Ning et al. (34) established that the increased expression of HNF4A inhibits HCC and alleviates hepatic fibrosis probably through the repression of beta-catenin signaling pathway, and proposed the administration of HNF4A as a possible future pathological treatment. Here, HNF4A is linked to hepatocellular carcinoma.